The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

This study tests a new combination therapy — LMV-12 plus osimertinib — in patients with advanced non-small cell lung cancer (NSCLC) whose tumors have specific genetic changes (MET amplification or RET fusion) and whose disease progressed after prior EGFR-targeting drugs. **You may be eligible if...** - You are 18 or older with advanced or metastatic NSCLC - Your cancer has a MET amplification or RET fusion (confirmed by testing) - Your cancer has stopped responding to first-, second-, or third-generation EGFR inhibitors - Your blood counts and organ function are within acceptable ranges - You are not pregnant or breastfeeding and agree to use contraception **You may NOT be eligible if...** - You have received recent medications that strongly interfere with the study drugs (CYP inhibitors/inducers) - You have had an organ transplant or bone marrow transplant - You have prior interstitial lung disease or radiation pneumonitis - You have active or significant hepatitis B, hepatitis C, or HIV - You have significant heart problems (severe arrhythmia, recent heart attack, heart failure) Talk to your doctor to see if this trial is right for you.